𝔖 Bobbio Scriptorium
✦   LIBER   ✦

D2 dopamine receptor polymorphism and brain regional glucose metabolism

✍ Scribed by Noble, Ernest P.; Gottschalk, Louis A.; Fallon, James H.; Ritchie, Terry L.; Wu, Joseph C.


Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
262 KB
Volume
74
Category
Article
ISSN
0148-7299

No coin nor oath required. For personal study only.

✦ Synopsis


Positron emission tomography (PET) studies have shown decreased glucose metabolism in brain regions of detoxified alcoholics and cocaine abusers. However, it is not clear whether this decrease is due to chronic drug abuse or a pre-existing condition. Molecular genetic studies have found an association of the D 2 dopamine receptor (DRD2) A1 allele with alcoholism and drug abuse. Moreover, reduced central dopaminergic function has been suggested in subjects who carry the A1 allele (A1 + ) compared with those who do not (A1 -). In the present study, using 18 Fdeoxyglucose, regional glucose metabolism was determined in healthy nonalcohol/ nondrug-abusing subjects with the A1 + or A1 -allele. The mean relative glucose metabolic rate (GMR) was significantly lower in the A1 + than the A1 -group in many brain regions, including the putamen, nucleus accumbens, frontal and temporal gyri and medial prefrontal, occipito-temporal and orbital cortices. Decreased relative GMR in the A1 + group was also found in Broca's area, anterior insula, hippocampus, and substantia nigra. A few brain areas, however, showed increased relative GMR in the A1 + group. Since polymorphism of the DRD2 gene is commonly observed in humans, the importance of differentiating A1 + and A1 - alleles subjects in PET studies is suggested.


πŸ“œ SIMILAR VOLUMES


Dopamine transporters, D2 receptors, and
✍ Stefanie Klaffke; Andrea A. Kuhn; Michail Plotkin; Holger Amthauer; Daniel Harna πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 59 KB

## Abstract Alterations in presynaptic and postsynaptic dopaminergic system and cerebral glucose metabolism in corticobasal degeneration (CBD) were assessed to evaluate the potential usefulness of different imaging methods for CBD. ^123^I‐FP‐CIT/^123^I‐β‐CIT SPECT and ^123^I‐IBZM SPECT as well as ^

Dopamine D2 receptor TaqI A polymorphism
✍ Mario Zappia; Grazia Annesi; Aldo Quattrone πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 9 KB

We read with interest the article by Grevle and colleagues, 1 reporting in Norway an association between the variant allele A1 of the TaqI A restriction fragment length polymorphism (RFLP) located in the dopamine D2 receptor (DRD2) gene and Parkinson's disease (PD). Similar findings have been report

D2 and D4 dopamine receptor polymorphism
✍ Noble, Ernest P.; Ozkaragoz, Tulin Z.; Ritchie, Terry L.; Zhang, Xuxian; Belin, πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 89 KB πŸ‘ 2 views

The relationship of various dimensions of temperament, measured by the Tridimensional Personality Questionnaire (TPQ), to polymorphisms of the D2 dopamine receptor (DRD2) and D4 dopamine receptor (DRD4) genes was determined in 119 healthy Caucasian boys who had not yet begun to consume alcohol and o

Dopamine D2 receptor TaqIA and TaqIB pol
✍ Eng-King Tan; Yanni Tan; Anthea Chai; Christopher Tan; Hui Shen; Sau-Ying Lum; S πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 248 KB πŸ‘ 1 views

## Abstract In a case control study, we examined the association of DRD2 Taq1A and Taq1B polymorphisms and risk of PD, and evaluated the strength of linkage disequilibrium of the polymorphisms. The Taq1A and Taq1B polymorphisms were in strong linkage disequilibrium. There was, however, no significa

Dopamine D2 receptor quantification in e
✍ Lars H. Pinborg; Charlotte VidebΓ¦k; Gitte M. Knudsen; Carl-Gunnar Swahn; Christe πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 130 KB

The iodinated benzamide epidepride, which shows a picomolar affinity binding to dopamine D(2) receptors, has been designed for in vivo studies using SPECT. The aim of the present study was to apply a steady-state condition by the bolus/infusion approach with [(123)I]epidepride for the quantification